Rubius Therapeutics (RUBY) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RUBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RUBY, but not buy additional shares or sell existing shares.
View RUBY analyst ratings or view top-rated stocks.

Rubius Therapeutics' stock was trading at $0.1750 at the start of the year. Since then, RUBY stock has decreased by 89.5% and is now trading at $0.0184.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our RUBY earnings forecast.

Rubius Therapeutics, Inc. (NASDAQ:RUBY) released its earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same quarter last year, the business posted ($0.51) earnings per share.

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Biopharma (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM).

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Rubius Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Dannielle Appelhans, David R Epstein, Laurence A Turka, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship.
View institutional ownership trends.

Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RUBY stock can currently be purchased for approximately $0.02.

Rubius Therapeutics (NASDAQ:RUBY) has a market capitalization of $1.66 million. The company earns $-179,670,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis.

The company employs 269 workers across the globe.

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The official website for the company is www.rubiustx.com. The company can be reached via phone at (508) 543-1720 or via email at ir@rubiustx.com.